The Results of the use of Teriparatide for Prevention in both Vertebral and Non-Vertebral Fractures in Postmenopausal Osteoporosis

Abstract

Background : Teriparatide , a synthetic parathyroid hormone ,increase the bone formation and bone mass . The known regimen is 20 mcg /day, through the subcutaneous injection. Method : Searching electronic database for its effect on prevention of both vertebral and non-vertebral fractures among postmenopausal women with osteoporosis . Results : Through 23 results, following the inclusion criteria , incidence of both vertebral and non-vertebral fractures was significantly decreased with teriparatide treatment , with different dosage (20mcg/day , 56.5 mcg/week and 28.2 mcg/week ) . Conclusion : teriaparatide decrease the risk of both vertebral and non-vertebral fractures among postmenopausal women with osteoporosis , and the effect on vertebral fractures being higher. Keywords: Teriparatide , postmenopausal osteoporosis , vertebral fracture , non-vertebral fractures , incidence of fracture ,